Imatinib
Imatinib Phase 2 (400 vs 600 mg)
Novartis · Phase 2 · Completed · Enrollment 147
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Imatinib 400 mg | KIT (CD117) positive unresectable or metastatic GIST | 400 mg | ITT | imatinib 600 mg | objective response rate (SWOG): 68.5%, up to 36 months |
| Imatinib 600 mg | KIT (CD117) positive unresectable or metastatic GIST | 600 mg | ITT | imatinib 400 mg | objective response rate (SWOG): 67.6%, up to 36 months |